Details for New Drug Application (NDA): 019090
✉ Email this page to a colleague
The generic ingredient in ZANTAC is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.
Summary for 019090
| Tradename: | ZANTAC |
| Applicant: | Pai Holdings Pharm |
| Ingredient: | ranitidine hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 25MG BASE/ML | ||||
| Approval Date: | Oct 19, 1984 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 019090
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pai Holdings Pharm | ZANTAC | ranitidine hydrochloride | INJECTABLE;INJECTION | 019090-001 | Oct 19, 1984 | ⤷ Get Started Free | ⤷ Get Started Free |
| Pai Holdings Pharm | ZANTAC | ranitidine hydrochloride | INJECTABLE;INJECTION | 019090-001 | Oct 19, 1984 | ⤷ Get Started Free | ⤷ Get Started Free |
| Pai Holdings Pharm | ZANTAC | ranitidine hydrochloride | INJECTABLE;INJECTION | 019090-001 | Oct 19, 1984 | ⤷ Get Started Free | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
